Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: An observational case series on behalf of the Grupo Espanol de Trasplante Hematopoyetico (GETH)

Autor: Cid, J, Monsalvo, S, Castillo, C, Pascual, C, Moreno-Jim, G, Lopez-Parra, M, Andon, C, Guerra, L, Esquirol, A, Sanchez-Ortega, I, Ortega, S, Zalba, S, Martinez, C, Rovira, M, Marin, P, Lozano, M
Rok vydání: 2021
Předmět:
Zdroj: TRANSFUSION AND APHERESIS SCIENCE
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
ISSN: 1473-0502
Popis: Plerixafor (Mozobil, Sanofi) is approved for using in patients with lymphoma and multiple myeloma when steady-state mobilization strategies fail. Although off-label use of plerixafor in healthy related donors (HRD) is known, limited data are available and no recommendations exist to guide its use in this setting. With the aim of collecting data from HRDs who received plerixafor in our country, we designed an observational case series study within the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH). Plerixafor was administered subcutaneously to 30 HRDs at a median dose of 0.24 mg/Kg (interquartile range (IQR): 0.23-0.25) because mobilization failure after using mobilization with G-CSF (mobilization failure was defined as collection of
Databáze: OpenAIRE
Externí odkaz: